Some Cancer Cells Can "Lie Low"

Cancer cells on standby—not gone. Explore what “lying low” means, how surviving cells can adapt, and what current research reveals about dormancy and treatment resistance.

Page 2 of the hub that unpacks the 2026 Cancer Stem Cells and Drug Resistance Review.

Many chemotherapy drugs work best against cells that are actively preparing to divide or are in the process of dividing. The 2026 review explains that some cancer stem-like cells can enter quiescence: a reversible slow-cycling or resting state, often described as cell-cycle arrest. In this state, the cell is alive, metabolically active and actively protecting itself—but it is not making a new copy of itself right now.

That distinction matters. A quiescent cancer cell is not necessarily dead, harmless or permanently disabled. It may simply be less exposed to treatments designed to interrupt DNA copying, chromosome separation or other parts of rapid cell division. If conditions later become more favourable, some cells may re-enter the cell cycle, begin dividing again and contribute to renewed tumour growth.

A useful image: If a rapidly dividing cancer cell is like a busy factory running full production, a quiescent cell is more like a factory that has gone into emergency standby. Its machines are quiet, its lights are low and it is producing very little—but it has not closed down. It may be conserving fuel, repairing damage, clearing waste, listening for signals from its environment and waiting for conditions in which it can restart.

Treatment can also act as a form of selection pressure: cells that remain in full production may be more likely to be eliminated, leaving behind cells that were already more protected or able to adapt. Some survivors later acquire or reveal more durable resistance through genetic change; others shift state without a new mutation. Both routes can contribute to relapse.

This is one reason an initial treatment response can be real and clinically valuable even if cancer later progresses. Treatment may substantially reduce tumour burden, symptoms, pain, obstruction risk, bleeding or the risk of urgent complications. In some cancers it can produce long-term disease control or cure. But a visible response does not always mean that every surviving cell has been eliminated. A small, slow-growing, protected or treatment-tolerant population may remain below the level that can be seen on a scan.

"Lying low" is not one state

The words quiescence, dormancy, treatment-tolerant persistence, senescence and autophagy are often used together online. They overlap, but they are not identical. Understanding the difference helps explain why there is no one simple strategy for "waking up" or eliminating residual cancer cells.

State	Plain-language description	Can the cell divide again?	Why it matters
Quiescence	A reversible pause in the cell cycle; the cell has stepped out of active division	Often yes	A cell may be less affected by treatments that work mainly on dividing cells
Dormancy	A longer-lasting state in which individual cells or small groups remain clinically silent or do not expand	Often yes, though timing is unpredictable	In some cancers, disseminated cells can remain below detection for years before later growing
Treatment-tolerant persistence	A small group of cells survives initial treatment through reversible adaptive changes, sometimes without a new permanent resistance mutation	Often yes	These cells may provide a temporary reservoir from which resistant disease later emerges
Senescence	A damaged or stressed cell enters a durable growth arrest and remains alive but no longer readily divides	Usually not, although biology is more complex than once thought	Senescent cells can release inflammatory signals and may influence nearby cells and the tumour environment
Autophagy	Cellular recycling: a cell breaks down and reuses damaged components, proteins and organelles	Not a cell-cycle state	It can help stressed, quiescent or dormant cells survive low nutrients, low oxygen and treatment damage

The boundaries are not always sharp. A cell can be quiescent while using autophagy; a dormant cell may share stem-like and treatment-tolerant features; and tumour-cell senescence can sometimes be less permanent than older textbooks implied. Researchers are still refining the definitions and working out which state is present in a particular cancer at a particular time.

How a cell enters standby mode

Quiescence is not passive. It is an actively controlled survival program.

The Hamdy review describes how CSC-like cells can respond to treatment stress by stepping out of the normal division cycle. A cell in this state may reduce the processes that make it vulnerable to cell-cycle-dependent therapy while strengthening systems that help it endure: DNA-damage sensing and repair, antioxidant control, anti-apoptotic signalling, metabolic adaptation and autophagy.

Signals from the tumour microenvironment can help reinforce this state. These may include:

Low oxygen, or hypoxia.
Limited nutrient supply.
Inflammation and stress signals.
Contact with blood vessels, fibroblasts or immune cells.
Changes in the stiffness and composition of surrounding tissue.
Treatment pressure itself.

This connects quiescence to the other sections in this hub. A cancer cell may lie low and repair DNA damage more effectively, pump drugs out, avoid apoptosis, recycle its internal components through autophagy, change its metabolism, or draw protection from its local neighbourhood. These are not competing explanations; they can work together.

Why conventional treatment may miss it

Chemotherapy is not one thing: different drugs work in different ways, and many treatments can affect cancer cells beyond cell division. Radiation, targeted therapy, endocrine therapy and immunotherapy also have different mechanisms. It would therefore be misleading to say that quiescent cells are invisible to all treatments.

The more accurate statement is that a cell that is not actively cycling can be relatively less sensitive to medicines whose greatest effect occurs while DNA is being copied or chromosomes are being separated. This can give slow-cycling cells a temporary survival advantage while faster-growing tumour cells are being reduced.

The central challenge is timing. If a cell is on standby during treatment, it may survive. If it later restarts growth, it may once again become more vulnerable to a cell-cycle-active therapy—but by then it may have acquired additional resistance mechanisms, be located in a protective niche, or have become part of a more heterogeneous recurrent tumour.

This is not a reason to distrust treatment. It is precisely why oncology today is using more combinations, treatment sequences, maintenance approaches, local therapy and repeated molecular assessment. The aim is to reduce the tumour in more than one way and to prevent surviving cells from finding an easy route back to growth.

Dormancy and late recurrence

The word dormancy is often used when cancer cells have travelled from the original tumour to another part of the body but have not yet formed a detectable growing metastasis. These disseminated cancer cells may remain in a non-proliferative or very slow-growing state for months, years or, in some cancer types, much longer.

This does not mean every person with cancer has dormant cells waiting to reactivate. Nor can current medicine reliably test every individual for them. Whether dormant cells are present, where they are located and what will cause them to grow again are major unanswered questions.

Researchers are studying possible "wake-up" influences, including changes in immune surveillance, inflammation, tissue injury, ageing, altered blood supply, fibrosis, changes in the local extracellular matrix and shifts in metabolic conditions. These are research themes—not proof that a particular stress, food, supplement, infection or life event directly caused an individual recurrence.

Why "wake them up" is not yet a solution

It is easy to hear that dormant cells resist treatment and conclude that the answer must be to force all cells to divide, then hit them with chemotherapy. Researchers have explored versions of this idea, but it is not a proven universal strategy.

There are two broad—but still experimental—ways researchers think about dormant or quiescent cancer cells:

Keep them contained: reinforce the conditions that maintain dormancy so they do not regrow.
Make them vulnerable: either wake them into a treatment-sensitive state or target the survival programs they rely on while dormant.

Both strategies carry risks. Reactivating cells could potentially encourage growth if the intended treatment does not eliminate them. Keeping cells dormant may not remove them. Targeting survival systems can also affect normal stem cells and healthy tissues. This is why the field is progressing cautiously through cancer-specific laboratory work and clinical trials rather than offering a general "dormancy protocol" for every cancer type or stage.

How this connects to autophagy and senescence

Our site's linked sections are important because they explain different parts of the same survival landscape.

Autophagy: A cell in low-energy, low-oxygen or treatment-stress conditions may recycle damaged mitochondria, proteins and other components to obtain materials and energy. In some models, this supports dormant-cell survival; blocking autophagy is therefore being studied as a way to expose a vulnerability. But autophagy can have different effects in different cancers and treatment settings.
Senescence: A cell may stop dividing after damage or therapy and enter a senescent state. This can initially suppress tumour growth, but senescent cells can remain alive and release inflammatory signals that affect neighbouring cells. Senescence is generally considered more durable than quiescence, although some therapy-induced senescent cancer cells may later regain proliferative capacity in particular contexts.
Dormancy: Dormancy is the clinical and ecological picture of cancer cells or small deposits remaining below the threshold of detectable expansion. Quiescence is one cellular mechanism that can contribute to it.

Circle back at a later date to our A-Z directory page to read more study support resources focused on:
Autophagy: How Cancer Cells Recycle for Survival - Senescence: The Second Escape Route - Dormancy: When Cancer Cells Remain Below Detection

What researchers are trying to do

There is no validated, general treatment that eliminates all quiescent CSC-like cells. However, the biology unpacked in this hub is guiding research into combination strategies that may:

Target active tumour cells and slow-cycling residual cells differently.
Interrupt autophagy or mitochondrial survival pathways.
Exploit redox, metabolic or DNA-repair vulnerabilities.
Disrupt protective signals from the tumour microenvironment.
Improve immune recognition of residual or dormant cells.
Identify biomarkers that show when a tumour is entering or leaving a treatment-tolerant state.

The realistic hope is not a one-size-fits-all "wake and kill" method.

Forming a better understanding of quiescence, dormancy, autophagy, senescence and CSC plasticity allows researchers to identify which surviving-cell program is most important in which cancer, then match it with a safer and more effective treatment combination.